(01-3627-JAG) (D NJ). Patent infringement action regarding Barr Laboratories’ ANDA for Aventis’s allergy product Allegra® (fexofenadine hydrochloride). Successful opposition to preliminary injunction and successful launch at risk for Barr.
(05-2308-JPS)(D.N.J.) Patent infringement action regarding Barr’s ANDA for Bayer’s contraceptive Yasmin® (drospirenone).
(02-9851) (SD NY). Patent infringement action regarding Barr Labs’ ANDA for Ferring’s urinary incontinence product DDAVP® (desmopressin acetate). Successfully rendered patent unenforceable.
(08-496-GMS) (D. Del.). Patent infringement action regarding Apotex’s ANDA for Sanofi-Aventis’ anti-cancer product TAXOTERE® (docetaxel). Two-week trial. Invalidated all claims and Sanofi’s patents ruled unenforceable.
(02-1844-SEB) (SD IN). Patent infringement action regarding Barr’s ANDA for Lilly’s osteoporosis product Evista® (raloxifene hydrochloride).
(08-534 and 08-970 – KSH) (D Del.). Patent infringement action regarding Sandoz’s ANDA for Endo’s pain product Opana® ER (oxymorphone hydrochloride). Settled favorably for Sandoz.
(09-033-JJF) (D Del.). Patent infringement action regarding Sandoz’s ANDA for Medicis’s acne product Solodyn® (minocycline hydrochloride). Settled favorably for Sandoz.
Review Nos. 2015-01976, -01980 and -01981. Invalidated all claims for Petitioner Amneal Pharma in IPR of U.S. Patent Nos. 8,232,250, 8,399,413 and 8,969,302, listed in the FDA Orange Book for Teva’s MS product Copaxone®.
(14-3962-JBS)(D. NJ) Represented Defendant Metrics in patent litigation over ANDA to make a generic version of Senju’s ophthalmic product Prolensa®. Settled favorably for Metrics.
(13-04507-CCC) (D. NJ) Full trial. Represented Actavis in patent litigation over ANDAs for Janssen’s pain products Nucynta® and Nucynta® ER. Successful ruling of non-infringement for Actavis.
(12-2474-FSH) (D. NJ) Patent litigation regarding Ranbaxy’s ANDA for Warner-Chilcott’s osteoporosis product Atelvia® (risedronate).
(17-11466) (D. Mass) Represented Dicerna in antitrust litigation with its competitor Alnylam in the RNA interference field. Settled favorably for Dicerna.
14-CV-01171 (GMS) (D.Del.) Successful invalidation of all claims in patent infringement action regarding Amneal’s ANDA to make a generic version of Teva’s MS product Copaxone® 40 mg.
(14-02025-SEB) (SD IN) Represented Amneal in full litigation, including trial, in patent infringement action over patents related to Lilly’s testosterone replacement product Axiron®.
(15-04126-EPL) (Mass. Sup. Ct.) Represented Dicerna in trade secret litigation regarding RNA interference technology. Settled before trial favorably for Dicerna.
(09-1302-DMC)(D NJ). Patent litigation regarding Wockhardt’s ANDA for Sepracor’s insomnia product Lunesta® (eszopiclone). Settled favorably for Wockhardt.
(12-2474-FSH) (D. NJ) Patent litigation regarding Ranbaxy’s ANDA for Warner-Chilcott’s osteoporosis product Atelvia® (risedronate).
(11-704-LPS) (D. Del.) Full trial. Patent infringement action regarding Wockhardt’s ANDA to make a generic version of Avanir’s PBA product Nuedexta®.
(07-05041-GEB) (D. N.J.). Full trial. Represented Actavis in patent action over ANDA for King’s pain product Avinza® (morphine sulfate). Settled successfully after trial.
